ELI LILLY & Co
Ticker: LLYHealthcarePharmaceutical PreparationsS&P 500The business
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and incorporated in Indiana in 1901. The company discovers, develops, manufactures, and markets human pharmaceutical products worldwide, with operations spanning the United States, including Puerto Rico, Europe, and Asia. Products are sold in approximately 90 countries.
The company operates as a single business segment focused on innovative medicines across four primary therapeutic areas: Cardiometabolic Health, Oncology, Immunology, and Neuroscience. Major cardiometabolic products include Mounjaro and Zepbound for diabetes and obesity treatment, Trulicity for type 2 diabetes, Jardiance for diabetes and heart failure, and various insulin formulations. The oncology portfolio includes Cyramza, Erbitux, Verzenio, Jaypirca, Retevmo, and Inluriya. Immunology offerings comprise Olumiant, Omvoh, Taltz, and Ebglyss. Neuroscience products include Emgality for migraine prevention and Kisunla for Alzheimer's disease.
Lilly's distribution strategy combines traditional wholesale channels with innovative direct-to-patient approaches through LillyDirect, its digital health platform. In the United States, three major wholesale distributors—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each account for significant portions of consolidated revenue. The company maintains its own sales organizations in many countries while utilizing third-party distribution arrangements in others.
The company's competitive positioning relies on intellectual property protection, including compound patents, data exclusivity, and trademark portfolios. Key products maintain patent protection through the 2020s and 2030s, with certain products benefiting from pediatric or orphan drug exclusivity extensions. Lilly faces competition from generic pharmaceuticals, biosimilars, and counterfeit products, particularly in the growing obesity medicine market where reimbursement barriers significantly impact sales volumes.
The company website is www.lilly.com. Lilly's long-term strategy centers on discovering and developing innovative, cost-effective products that deliver improved patient outcomes while maintaining operational efficiency in a highly competitive global pharmaceutical environment.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- HQ
- INDIANAPOLIS, IN
- FY end
- 12-31
- CIK
- 59478
- SIC
- 2834
Ownership
Who holds ELI LILLY & Co — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 1.40% | $32.27B |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 1.47% | $24.59B |
| iShares Core S&P 500 ETF IVV · iShares Trust | 1.47% | $13.05B |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust SPY | 1.47% | $11.50B |
| Fidelity 500 Index Fund FXAIX · Fidelity Concord Street Trust | 1.35% | $11.21B |
Superinvestors in ELI LILLY & Co
Share of each manager's reported 13F portfolio.
Bonds held by funds
Funds report holding 54 issues of ELI LILLY & Co's debt, $5.20B at fund-held market value — what funds hold, not the company's debt outstanding. Weighted-average coupon 4.67%, maturing 2026–2066.
| Issue | Coupon | Matures | Funds | Fund-held |
|---|---|---|---|---|
| ELI LILLY & CO SR UNSEC 5.1% 02-12-35 | 5.100% | 2035-02-12 | 58 | $322.72M |
| Eli Lilly & Co | 4.850% | 2036-05-20 | 54 | $241.18M |
| Eli Lilly & Co | 4.180%Floating | 2028-10-15 | 27 | $235.75M |
| ELI LILLY & CO | 4.900% | 2035-10-15 | 64 | $221.38M |
| ELI LILLY & CO SR UNSEC 5.5% 02-12-55 | 5.500% | 2055-02-12 | 63 | $195.28M |
| Eli Lilly & Co | 4.700% | 2034-02-09 | 80 | $192.63M |
| LLY 4.375 05/20/31 | 4.375% | 2031-05-20 | 54 | $185.41M |
| Eli Lilly & Co | 4.550% | 2032-10-15 | 50 | $182.71M |
| LLY 4.75 02/12/30 | 4.750% | 2030-02-12 | 72 | $179.24M |
| Eli Lilly & Co | 4.650% | 2033-05-20 | 43 | $178.57M |
The 10 largest by fund-held value, of 54.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of ELI LILLY & Co's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free